DrugandAlcoholDependence115 (2011) 190–195
ContentslistsavailableatScienceDirect
Drug and Alcohol Dependence
journal homepage: www.elsevier.com/locate/drugalcdep
Rates and correlates of mortality amongst heroin users: Findings from the
Australian Treatment Outcome Study (ATOS), 2001–2009
ShaneDarke∗,KatherineL.Mills,JoanneRoss,MareeTeesson
NationalDrugandAlcoholResearchCentre,UniversityofNewSouthWales,Sydney,NSW2052,Australia
a r t i c l e i n f o a b s t r a c t
Articlehistory: Thestudyaimedtodeterminemortalityrates,standardisedmortalityratios(SMRs),andcorrelatesof
Received4August2010 mortalityamongsttheAustralianTreatmentOutcomeStudy(ATOS)cohortof615heroinusersover
Receivedinrevisedform theperiod2001–2009.Thecohortwasfollowedforatotalof4820.1personyears.Atotalof31deaths
20September2010
(5%ofthecohort)occurredacrossfollow-up.Themeanageatdeathwas34.5years,and58%were
Accepted12October2010
male.Themostcommoncauseofdeathwasoverdose(68%).Thecrudemortalityratewas6.43per
Available online 3 December 2010
1000personyears,withnogenderdifference,andtheSMRwas4.56(males=2.95,females=18.57).The
onlysignificantbivariate(hazardratio=3.69)andmultivariate(adjustedhazardratio=3.03)correlateof
Keywords:
mortalitywasahistoryofopioidoverdosepriortobaseline.Mortalityrateswerelowerthanthoseseen
Heroin
Mortality outsideAustralasia.Screeningforoverdosebythosetreatingheroinuserswouldbeappropriate,andmay
Overdose contributetoreductionsinoverallmortality.
Longitudinal © 2010 Elsevier Ireland Ltd. All rights reserved.
ATOS
1. Introduction suicideandtraumaplayfargreaterroles(Oppenheimeretal.,1994;
Antolinietal.,2006;Bargaglietal.,2006;Baueretal.,2008;Soyka
Globally,opioidsmakethelargestcontributiontoillicitdrug- etal.,2006;Vlahovetal.,2008;Degenhardtetal.,2009).Anumber
relateddeath,carryahighermortalityriskthanothercommonly ofpredictorsofmortalityhavebeenidentified.Theseincludenot
used drugs, and are associated with annual mortality rates typi- beingenrolledindrugtreatment,injectingasarouteofadministra-
callyrangingbetweenoneandthreepercent(Bartuetal.,2004; tion,HIVpositiveserostatus,olderage,alongerheroinusingcareer,
Darke et al., 2007a; Miller et al., 2007; Bauer et al., 2008; Bird, polydruguse,thepresenceofclinicallysignificantpsychopathology
2010; Stenbacka et al., 2010). It is worth noting that mortality andasuicidehistory(Quaglioetal.,2001;Bartuetal.,2004;Brugal
ratesvaryconsiderablybygeographicregion.Ratesappearhigh- etal.,2005;Soykaetal.,2006;Darkeetal.,2007a;Azimetal.,2008;
est in Asia, being approximately twice those of western Europe, Baueretal.,2008;Clausenetal.,2008;Stooveetal.,2009).Baseline
threetimesthoseofNorthAmericaandfivetimesthoseofAus- predictorsareofpotentiallygreatclinicalimportancefordetermin-
tralasia(Zhangetal.,2005;Bargaglietal.,2006;Milleretal.,2007; ingthemortalityriskofpatientsattreatmentin-take,whichmay
Quanetal.,2007;Azimetal.,2008;Vlahovetal.,2008;Degenhardt affecttreatmentdelivery.
etal.,2009;Bird,2010).Thismayreflectdifferencesinunderlying Thecurrentstudyaimedtoexaminemortalityrates,andcor-
regionalpopulationmortalityrates,aswellasdifferencesinaccess relates,amongsttheAustralianTreatmentOutcomeStudy(ATOS)
todrugtreatmentandhealthcare. cohort over the period from commencement in February 2001
The major causes of death are overdose, disease (predomi- until October 2009. The cohort consists of entrants to treatment
nantlyAIDS),suicideandtrauma(Bartuetal.,2004;Antolinietal., forheroindependenceinopioidmaintenance,detoxification,and
2006;Soykaetal.,2006;Bargaglietal.,2006;Darkeetal.,2007a; residential rehabilitation, as well as a comparison group of non-
Degenhardtetal.,2009).Therelativecontributionofthese,how- treatment users. The Australian setting for the cohort has a HIV
ever,variesconsiderablyacrosscountries.Incountrieswithahigh seroprevalenceamongstIDUoflessthantwopercent,withpop-
HIVseroprevalenceamongstinjectingdrugusers(IDU),AIDSisa ulation wide access to free health care (Mathers et al., 2008). At
majorcauseofdeath,whileinlowprevalencecountriesoverdose, baseline,awiderangeofdruguse,overdose,psychological,health
andpsychosocialmeasureswerecollected(Rossetal.,2005).These
datawereusedtodeterminewhatweretheclinicallyimportant
∗ baselinecharacteristicspredictdeathoverthestudyperiod,asin
Correspondingauthor.Tel.:+610293850234;fax:+610293850222.
E-mailaddress:s.darke@unsw.edu.au(S.Darke). similarotherstudiesofopioidusers(Gossopetal.,2002).
0376-8716/$–seefrontmatter© 2010 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.drugalcdep.2010.10.021
S.Darkeetal./DrugandAlcoholDependence115 (2011) 190–195 191
Specifically,thestudyaimedto: interviewdateuntildateofdeathorcensorshipatOctober2010,
whenthesearchwasconducted.Crudemortalityratesper1000
1. DeterminethemortalityratesoftheATOScohort. personyears(PY)with95%confidenceintervals(CI)werecalcu-
2. Determinestandardisedmortalityratios(SMRs)forthecohort, lated,aswerestandardisedmortalityratios(SMRs)byreferenceto
stratifiedbygender. age specific death rates in the Australian population (Australian
3. Determine bivariate and multivariate associations of baseline Bureau of Statistics, 2010). Bivariate Cox proportional hazards
characteristicswithmortalityrates. regressionswereperformedtodetermineunadjustedhazardratios
(HR)forbaselinecharacteristicsinthedomainsofdemographics,
2. Methods druguse,overdose,suicide,psychopathologyhealthandcrime.In
ordertodetermineindependentpredictorsofmortality,amulti-
2.1. Procedure variateCoxproportionalhazardsregressionwasconducted.Age,
sexandallvariableswithapvalue<0.1fromthebivariateanalyses
The data were collected as part of ATOS. Baseline interviews wereenteredintothemodel.Allanalyseswereconductedusing
were conducted between February 2001 and August 2002, with PASW,Release18(SPSSInc.,2009).
threemonth(89%followedup),12month(80%),24month(76%)
and 36 month (70%) follow-up interviews conducted. Prior to
3. Results
recruitment,alltreatmentagenciesinthethreemodalitiesacross
thegreaterSydneyregionweremapped.Agencieswerethenran-
3.1. Cohortcharacteristicsatbaseline
domlyselected,stratifiedbymodalityandareahealthservice.The
agencies comprised ten methadone/buprenorphine maintenance
The mean age of participants was 29.3 years (SD 7.8, range
(MT) agencies, four drug free residential rehabilitation agencies
18–56), and 66% were male. The sample had completed a mean
(RR)andninedetoxificationfacilities(DTX).Inaddition,agroupof
of 10.0 years of secondary education (SD 1.7, range 2–12), 29%
heroinusersnotcurrentlyintreatment(NT)wererecruitedfrom
had completed a trade/technical course, and six percent a uni-
needle and syringe programs in the regional health areas from
versitydegree.Themainsourcesofincomewere:socialsecurity
which treatment entrants were recruited. Ethics approvals were
allowances (46%), criminal activity (24%) and wage/salary (18%).
obtained from the University of New South Wales, and all rele-
It should be noted that these are main, and not sole, sources of
vantareahealthservices.Eligibilitycriteriawere:(i)notreatment
income.
forheroindependenceintheprecedingmonth,(ii)noimprison-
Themeanageoffirstintoxicationwas13.7years(SD3.3,range
mentintheprecedingmonth,(iii)agreedtogivecontactdetails
2–34years).Themeanageoffirstheroinusewas19.6years(SD5.3,
for follow-up interviews, (iv) aged 18 years or over, and (v) flu-
range9–43years),andthemeanlengthofheroinusecareerattime
entinEnglish.Thetotalbaselinecohortwas615heroinusers:MT
ofinterviewwas9.5years(SD7.4,range<1–35years).Thesam-
(n=201),DTX(n=201),RR(n=133)andNT(n=80).Participants
plehadusedheroinonameanof20.1days(SD8.1,range1–28)
wereinterviewedatbaseline,andat3,12,24and36monthspost-
inthefourweeksprecedinginterview,54%reportedahistoryof
baseline,andpaidA$20forcompletionofeachinterview.Asearch
heroinoverdose,and8%werenon-injectors.Thesamplehadused
oftheAustralianNationalDeathIndexwasconductedinOctober
ameanof9.0(SD1.7,range3–11)drugclassesintheirlives,and
2009,anddetailsofdeathsthathadoccurredamongstparticipants
4.8(SD1.7,range2–9)intheprecedingmonth.Ninetypercenthad
since2001wasobtained.Participantswerematchedbyfullname,
previouslybeenenrolledinatreatmentprogramforopiatedepen-
genderanddateofbirth.
dence.ThemeanSF12globalphysicalhealthscorewas43.9(SD
9.8,range15.5–65.4)andthemeanglobalhealthscorewas31.7
2.2. Structuredinterview
(SD11.1,range8.9–67.3).Adiagnosisofcurrent(1month)major
depressionwasreceivedby25%,and33%hasattemptedsuicide.
Atbaseline,participantswereadministeredastructuredinter-
FortyonepercentmetcriteriaforalifetimediagnosisofPTSD,46%
view that included demographics, treatment history, drug use
foradiagnosisofBPDand73%forASPD.
history, overdose history, suicide history and a range of psy-
Acrossthe36monthfollow-upperiodofATOS,therewassub-
chopathology. Drug use, needle sharing, injection-related health
stantialcross-overbetweentreatmentmodalities(Teessonetal.,
problemsandcriminalbehavioursoverthemonthprecedinginter-
2008). Amongst the NT group, 93% received some form of treat-
viewweremeasuredusingtheOpiateTreatmentIndex(OTI)(Darke
mentby36months(MT40%,RR21%,DTX50%).Similarly,there
etal.,1992).Current(1month)globalmentalandphysicalhealth
wassubstantialcrossoverbetweenbaselinetreatmentgroups:MT
were measured using the Short-Form 12 (SF12), in which lower
(RR5%andDTX11%),RR(MT26%andDTX36%)andDTX(MT33%
scoresindicatepoorerhealth(mean=50,standarddeviation=10)
andRR37%).
(Wareetal.,1996).DSMIVdiagnosesofcurrent(1month)Major
depressionandlifetimePostTraumaticStressDisorder(PTSD)were
obtainedusingtheCompositeInternationalDiagnosticInterview 3.2. Mortality
(CIDI)(WorldHealthOrganization,1993).DiagnosesofAntisocial
Personality Disorder (ASPD) were obtained from the Diagnos- Thecohortwasfollowedforatotalof4820.1PY.Atotalof31
tic Interview Schedule (Robins et al., 1981), modified to obtain deaths (5%) occurred across follow-up, of which 18 (58%) were
DSM IV diagnoses. International Classification of Diseases (10th male. The crude mortality ratio was 6.43 per 1000 PY (95% CI
edition)(ICD-10)diagnosesofBPDwereobtainedusingtheInter- 4.37–9.13 per 1000 PY), with no significant gender difference
nationalPersonalityDisordersExaminationQuestionnaireusedin (Table1).TheSMRforthecohortwas4.56(CI3.09–6.47).Males
theNationalSurveyofMentalofHealthandWellbeing(Andrews hadaSMRof2.95(CI1.75–4.66)andfemales18.57(CI9.89–31.52).
etal.,1999). Causesofdeathwere:overdose(n=19,68%),disease(n=7,23%)
andsuicide(n=2,7%).In3casesthecauseofdeathwasunknown,
2.3. Statisticalanalyses duetolagsintheNationalDeathIndexinprovidingfulldetailsof
adeath.Ofthe19knownoverdosefatalities,16hadahistoryof
Means and standard deviations were reported for continuous overdosepriortoenrolmentinATOS,andbothsuicideshadmade
variables.Personyearsoffollow-upwerecalculatedfrombaseline attemptspriortoATOSenrolment.
192 S.Darkeetal./DrugandAlcoholDependence115 (2011) 190–195
Table1
Unadjustedandadjustedhazardratioforallcausemortalityamongst615heroinusers.
Characteristics No. No.deaths Personyears Mortalityrate(per1000PY) Multivariatestatistics
Unadjustedhazardratio Adjustedhazardratio
Total 615 31 4820.1 6.43(CI4.37–9.13) – –
Demographics
Age(Years)
≥30 229 16 1767.3 9.05(CI5.18–14.70) 1.84(CI0.82–4.10) 1.79(CI0.87–3.68)
<30 386 15 3052.8 4.91(CI2.75–8.10)
Sex
Male 407 18 3195.4 5.63(CI3.34–8.90) 0.70(CI0.35–1.44) 0.76(CI0.35–1.62)
Female 208 13 1624.6 8.00(CI4.26–13.68) 1.00
Previoustreatment
Yes 545 28 4278.7 6.54(CI4.35–9.46) 1.17(CI0.36–3.85) –
No 69 3 541.4 5.54(CI1.14–16.20) 1.00
Enteringtreatment
Yes 535 27 4196.3 6.43(CI4.24–9.36) 1.00(CI0.35–2.88) –
No 80 4 623.8 6.41(CI1.77–16.42) 1.00
Modalities
Maintenance 201 7 1596.8 4.38(CI1.76–9.03) 0.67(CI0.20–2.30) –
Detoxification 201 10 1578.4 6.34(CI3.04–11.65) 0.98(CI0.31–3.11) –
Residentialrehabilitation 131 10 1021.0 9.79(CI4.70–18.01) 1.53(CI0.48–4.86) –
Non-Treatment 80 4 623.8 6.41(CI1.75–16.42) 1.00
Druguse
Lengthofcareer(Years)
>5 382 23 2966.4 7.75(CI4.92–11.63) 1.84(CI0.82–4.10) –
≤5 233 8 1853.7 4.32(CI1.86–8.50) 1.00
Heroininjector
Yes 567 29 4435.7 6.54(CI4.38–9.39) 1.25(CI0.30–5.25) –
No 48 2 384.3 5.20(CI0.63–18.80) 1.00
Heroinuse(1month)
Daily 489 24 3834.2 6.26(CI4.01–9.31) 0.88(CI0.38–2.03) –
Lessthandaily 126 7 985.8 7.10(CI2.85–14.63) 1.00
Alcohol(1month)
Yes 327 17 2552.4 6.66(CI3.88–10.66) 1.08(CI0.53–2.20) –
No 288 14 2267.7 6.17(CI3.38–10.36) 1.00
Benzodiazepines(1month)
Yes 294 20 2287.0 8.75(CI5.34–13.51) 2.00(CI0.96–4.18) 1.59(CI0.75–3.53)
No 321 11 2533.0 4.34(CI2.17–7.77) 1.00
Antidepressants(1month)
Yes 87 8 678.8 11.79(CI5.09–23.22) 2.07(CI0.93–4.63)
No 528 23 4141.3 5.55(CI3.52–8.33) 1.00
Overdosed(Ever)
Yes 334 25 2573.4 9.71(CI6.29–14.34) 3.69(CI1.51–9.90)a 3.03(CI1.22–7.52)a
No 281 6 2246.7 2.67(CI0.98–5.81) 1.00
Suicideattempt(Ever)
Yes 205 15 1596.5 9.40(CI5.26–15.50) 1.90(CI0.94–3.84) 1.40(CI0.66–2.96)
No 410 16 3223.5 4.96(CI2.84–8.06) 1.00
Psychopathology
Severedisability(SF12)
Yes 303 18 2370.7 7.59(CI4.50–12.01) 1.42(CI0.70–2.90) –
No 312 13 2449.4 5.31(2.83–7.42) 1.00
Majordepression
Yes 151 11 1170.6 9.40(CI4.69–16.81) 1.74(CI0.83–3.62) –
No 464 20 3649.5 5.48(CI3.35–8.46) 1.00
PTSD
Yes 253 16 1977.5 8.09(4.62–13.14) 1.54(CI0.76–3.11) –
No 362 15 2842.5 5.28(2.95–8.70) 1.00
ASPD
Yes 440 20 3460.7 5.78(CI3.53–8.93) 0.71(CI0.34–1.48)
No 175 11 1359.3 8.09(CI4.04–14.48) 1.00 –
BPD
Yes 280 17 2168.4 7.84(CI4.57–12.55) 1.51(CI0.74–3.06)
No 335 14 2651.7 5.28(CI2.89–8.86) 1.00 –
Health
Severedisability(SF12)
Yes 53 2 415.8 4.81(CI0.58–17.38) 0.75(CI0.18–3.14) –
No 562 29 4404.3 6.58(CI4.41–9.56) 1.00
Crime(1month)
Yes 336 18 2635.9 6.83(CI4.05–9.28) 1.14(CI0.56–3.32) –
No 279 13 2184.2 5.95(CI3.17–10.18) 1.00
a Significantassociation.
S.Darkeetal./DrugandAlcoholDependence115 (2011) 190–195 193
The mean age at death was 34.5 years (SD 8.1, range 20–55 dominated the cause of death (Bartu et al., 2004; Digusto et al.,
years),withnodifferencebetweenmalesandfemales(36.2v33.0, 2004;Taitetal.,2008;Degenhardtetal.,2009).IntheAustralian
p=0.28).Themeanelapsedtimebetweenbaselineanddeathwas settingitistheriskofoverdosethatposesthesinglegreatestthreat
4.4years(SD2.4,range0.2–8.0years),andmeanlengthofheroin tothelifeoftheactiveheroinuser.Interestingly,therewasnodis-
use 15.2 years (SD 8.6, range 1–32 years). There were no differ- cernabledifferencebetweensingleormultipleoverdosehistories
encesbetweentheindextreatmentgroupsintheproportionsof prior to baseline. It is an overdose history per se that is of clini-
decedents(p=0.44):MT(3.5%),RR(7.5%),DTX(5.0%)andNT(5.0%). calrelevanceformortalityrisk.Thefactthatanoverdosehistory
predictedsubsequentmortalityisconsistentwithearlierstudies
ofnon-fataloverdoseinwhichapriorhistoryofoverdosestrongly
3.3. Predictorsofmortality
predictedfuturenon-fataloverdose(Cooketal.,1998;Powisetal.,
1999;Coffinetal.,2007;Darkeetal.,2007c).AmongsttheATOS
Theonlysignificantbivariateassociationwithmortalitywasa
cohortovertheinitial36months,anoverdoseinanyoneyearwas
historyofopioidoverdose(Table1).Therewasnosignificantdif-
associatedwithanapproximatelysixfoldincreaseintheriskofan
ferenceinmortalityratesforthosewhohadoverdosedonasingle
overdoseinthesubsequentyear(Darkeetal.,2007c).Thecurrent
occasion(11.4395%CI5.24–21.72per1000PY)andthosewhohad
studyindicatesthatthisriskextendstopredictingdeath.Indeed,
overdosedonmultipleoccasions(8.96,95%CI5.12–14.54per1000
ofthe19knownoverdosedeaths,16hadoverdosedpriortoATOS
PY)Therewerenosignificantassociationswithdemographicchar-
enrolment.Thedataareconsistentwithretrospectivedataofthose
acteristics,lengthofdrugusecareer,pastmonthheroinandother
previouslyattendedforoverdose,whereoverdosewasassociated
drug use, suicide history, psychopathology, baseline health (one
withsubsequentriskofoverdosemortality(Stooveetal.,2009).
month)orbaselinecriminalactivity(onemonth).
Similarly,bothknownsuicideshadhistoriesofsuicideattempts,
Inordertodetermineindependentpredictorsofmortalityand
consistentwiththecohort’spatternofpastattemptsstronglypre-
adjusted hazard ratios, a multivariate Cox proportional hazards
dictingfutureones(Darkeetal.,2007b).
regression was conducted. Age (years), sex (Male=1, Female=0)
The study is also of interest for what did not predict mor-
and all variables with a p value <0.1 from the bivariate analyses
tality. The most salient example was the absence of difference
wereenteredintothemodel:baselinebenzodiazepineuse(Yes=1,
between those entering the treatment modalities and those not
No=0),baselineantidepressantuse(Yes=1,No=0),overdosehis-
seeking treatment. As discussed earlier, treatment is associated
tory (Yes=1, No=0), baseline suicide attempt history (Yes=1,
withreduceddruguseandmortality(Soykaetal.,2006;Clausen
No=0). Again, the only significant predictor of mortality was a
et al., 2008; Degenhardt et al., 2009). The natural history of the
historyofoverdosepriortobaseline(Table1).
cohort,however,erodedthevalidityofsuchcomparisons.By12
months, three quarters of the NT group had entered drug treat-
4. Discussion ment,andover90%haddonesoby36months(Rossetal.,2006;
Teessonetal.,2008).Similarly,therewassubstantialmovement
Severalmajorfindingsemerged.First,thecohortdiedatfourand between the treatment modalities across time, which confounds
ahalftimestheexpectedpopulationrate,andatratesconsistent anycomparativeanalysesofmortalityratesbetweenmodalities.
withearlierAustralianstudies.Second,overdosewasoverwhelm- Routeofadministrationalsodidnotpredictmortality,despitebeing
inglythemajorcauseofdeath.Finally,andrelatedtothis,overdose associated with lower rates of non-fatal overdose in the cohort
historywastheonlysignificantpredictorofmortality. (Darkeetal.,2008),andbeingassociatedwithlowerdeathrates
Thecrudemortalityrateofthecohortwasconsistentwithear- in other studies (Bird, 2010). As with treatment, however, com-
lierAustralianstudiesofopioidusers(Bartuetal.,2004;Digusto parisonswereerodedbythefactthattransitionsbetweenroutes
et al., 2004; Tait et al., 2008; Degenhardt et al., 2009), and was occurred, primarily from non-injecting to injecting (Darke et al.,
substantially lower than those seen in Europe, Asia and North 2008). No form of psychopathology predicted death, in all prob-
America (Zhang et al., 2005; Bargagli et al., 2006; Miller et al., abilityreflectingtheroleofoverdose,ratherthansuicide,asthe
2007;Quanetal.,2007;Vlahovetal.,2008;Bird2010).Inallprob- predominantcauseofdeath.Theabsenceofhealthasapredictor
ability this reflects the very low rates of HIV infection amongst reflectsthelowrateofHIVamongstAustralianopioidusers,andthe
Australian opioid users. In all Australian mortality studies con- relativehealthofthecohort.Whiletheglobalhealthofthecohort
ducted to date, disease has played a negligible role in mortality washalfastandarddeviationbelowthepopulationnormatbase-
comparedtocohortsfromotherregions.Asnotedabove,itmayalso line,by12monthsthecohortaveragehadimprovedtopopulation
partiallyreflecttherelativeeaseofaccesstofreedrugtreatmentin norms(Teessonetal.,2008).
theAustralianhealthsystem. Themajorimplicationofthisresearchfortreatmentagencies
The demographic characteristics of decedents were typical of concernsscreeningforoverdosehistories.Overdosewasthemajor
opioiddeathsworldwide,inthattheywerepredominantlymale, causeofdeath,andahistoryofoverdoseincreasedtheriskofdeath
agedonaverageintheirthirties,injectorsandhadlongheroinuse three fold across follow-up. Indeed, it was only overdose histo-
careers.Despitethepredominanceofmalefatalities,therewasno riesthatpredicteddeath.Screeningforoverdosehistorieswould
genderdifferenceinmortalityrates,whichisconsistentwiththe appearprudentindeterminingpatientrisk,bothforoverdoseand
bulkofstudiesinternationallythatreportsmall,orno,genderdif- death,andtailoringinterventionforhighriskpatients.
ferences(Oppenheimeretal.,1994;Sanchez-CarbonellandSeus, Asinallstudies,caveatsmustbeborneinmind.First,caution
2000;Bartuetal.,2004;Darkeetal.,2007a;Bargaglietal.,2006; shouldbeexercisedinextendingconclusionstootherheroinusing
Baueretal.,2008;Stenbackaetal.,2010).Consistentwithearlier populations.TheATOScohort,likemostcohorts,wasregularheroin
work,however,femaleSMRsweresubstantiallyhigherthanthose users,withanextensiveprevioustreatmenthistory.Theremaywell
of males, reflecting the lower base population mortality rate of bedifferencesinmortalityratesandcorrelatesamongstlessfre-
females.Ifthemortalityratesofmaleandfemaleillicitdrugusers quentheroinusers.Itmustbeborneinmind,however,thatthe
aresimilar,ashere,theSMRoffemaledruguserswillalwaysbe overwhelming demographics of death amongst heroin users are
far greater compared to other females, than for male drug users long-termusers,similarincharacteristicstotheATOScohort.Sec-
comparedtoothermales. ond,theexclusionofthosewhohadbeeninprisoninthemonth
Consistent with earlier Australian research, and the status of prior to baseline interview should be borne in mind, as this is a
AustralianIDUasalowHIVseroprevalencepopulation,overdose highriskperiod.Third,officialstatisticsarealwayspronetolags
194 S.Darkeetal./DrugandAlcoholDependence115 (2011) 190–195
andpossibleomissions.Wewerethusnotabletodeterminethe Bird,S.M.,2010.Over1200drugs-relateddeathsand190,000opiate-users-years
causeofdeathforthreecases.Finally,thedetailedtreatmentand offollow-up:relativerisksbysexandagegroup.Addict.Res.Theory18,194–
207.
lifeeventshistoryofthecohortacrosstheperiodwereunknown,
Brugal,M.T.,Domingo-Salvany,A.,Puig,R.,Barrio,G.,GarciadeOlalla,P.,delaFuente,
andfollow-upinterviewswererestrictedto36months.Asnoted L.,2005.Evaluatingtheimpactofmethadonemaintenanceprogrammesonmor-
above, however, this was a study of clinically relevant baseline talityduetooverdoseandAIDSinacohortofheroinusersinSpain.Addiction
100,981–989.
characteristicsthatmightbeofuseindeterminingthemortality
Clausen,T.,Anchersen,K.,Waal,H.,2008.Mortalitypriorto,during,andafteropioid
riskfornewtreatmententrants.Also,thenaturalhistoryoftreat- maintenancetreatment(OMT):anationalprospectivecross-registrystudy.Drug
mentmeansthatanycomparisonbetweenthemodalitieswould AlcoholDepend.94,151–157.
beconfoundedbyexposuretoenrolmentsinmultiplemodalities. Coffin,P.O.,Tracy,M.,Bucciarelli,A.,Ompad,D.,Vlahov,D.,Galea,S.,2007.Inden-
tifyinginjectingdrugusersatriskofnonfataloverdose.Acad.Emerg.Med.14,
Insummary,deathratesamongstthiscohortwerelowerthan 616–623.
those seen outside Australasia. Overdose dominated the deaths Cook,S.,Moeschler,O.,Michaud,K.,Yersin,B.,1998.Acuteopiateoverdose:charac-
amongstthecohort,andanoverdosehistorywasthesolepredictor teristicsof190consecutivecases.Addiction93,1559–1569.
Darke,S.,Degenhardt,L.,Mattick,R.,2007a.MortalityAmongstIllicitDrugUsers:
ofmortality.Screeningforoverdosebythosetreatingheroinusers
Epidemiology,CausesandIntervention.CambridgeUniversityPress,Cambridge.
wouldbeappropriate,andmaycontributetoreductionsinoverall Darke, S., Hall, W., Heather, N., Wodak, A., Ward, J., 1992. Development and
mortality. validationofamulti-dimensionalinstrumentforassessingoutcomeoftreat-
mentamongopioidusers:theOpiateTreatmentIndex.Br.J.Addict.87,593–
602.
Roleofthefundingsource Darke,S.,Ross,J.,Mills,K.L.,Williamson,A.,Havard,A.,Teesson,M.,2008.Injecting
andnon-injectingheroinadministration:transitionsandtreatmentoutcomes
across36months.J.DrugIssues38,543–558.
ThisresearchwasfundedbytheNationalHealthandMedical Darke,S.,Ross,J.,Williamson,A.,Mills,K.L.,Havard,A.,Teesson,M.,2007b.Patterns
ResearchCouncil,andtheAustralianGovernmentDepartmentof andcorrelatesofattemptedsuicidebyheroinusersoverathreeyearperiod.
FindingsfromtheAustralianTreatmentOutcomeStudy.DrugAlcoholDepend.
HealthandAgeing.Thefundingsourcehadnoroleinstudydesign;
87,146–152.
in the collection, analysis or interpretation of data; in the writ- Darke, S., Ross, J., Williamson, A., Mills, K.L., Havard, A., Teesson, M., 2007c.
ingofthereport;orinanydecisiontosubmitthemanuscriptfor Patterns of non-fatal heroin overdose over a three year period. Findings
from the Australian Treatment Outcome Study. J. Urban Health 84, 283–
publication.
291.
Degenhardt,L.,Randall,D.,Hall,W.,Law,M.,Butler,T.,Burns,L.,2009.Mortality
amongclientsofastate-wideopioidpharmacotherapyprogramover20years,
Contributors
riskfactorsandlivessaved.DrugAlcoholDepend.105,9–15.
Digusto, E., Shakeshaft, A., Ritter, A., O’Brien, S., Mattick, R.P., NEPOD Study
ProfessorDarkewasinvolvedinthedesignofthestudy,data Group, 2004. Serious adverse events in the Australian National Evaluation
analysis,andwrotethefirstdraftofthemanuscript.DrMillswas of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction 99, 450–
460.
involvedindatacollection,statisticalanalysisandthewritingof Gossop,M.,Steward,D.,Treacy,S.,Marsden,J.,2002.Aprospectivestudyofmor-
thereport.DrRosswasinvolvedinthedesignofthestudy,study talityamongdrugmisusersduringafouryearperiodafterseekingtreatment.
co-ordinationandthewritingofthereport.ProfessorTeessonwas Addiction97,39–47.
Mathers,B.,Degenhardt,L.,Phillips,B.,Wiessing,L.,Hickman,M.,Strathdee,S.,
involvedinthedesignofthestudy,projectcoordination,andthe
Wodak,A.,Panda,S.,Tyndall,M.,Toufik,A.,Mattick,R.,forthe2007Reference
writingofthereport. GrouptotheUNonHIV,InjectingDrugUse,2008.Globalepidemiologyofinject-
ingdruguseandHIVamongpeoplewhoinjectdrugs,asystematicreview.Lancet
372,1733–1745.
Conflictofinterest Miller,C.L.,Kerr,T.,Strathdee,S.A.,Li,K.,Wood,E.,2007.Factorsassociatedwith
prematuremortalityamongyounginjectiondrugusersinVancouver.Harm
Reduct.J.4,doi:10.1186/1447-7517-4-1.
Therearenoconflictsofinteresttodeclareforanyauthor.
Oppenheimer,E.,Tobutt,C.,Taylor,C.,Andrew,T.,1994.Deathandsurvivalina
cohortofheroinaddictsfromLondonclinics,a22yearfollow-up.Addiction89,
1299–1308.
Acknowledgments
Powis,B.,Strang,J.,Griffiths,P.,Taylor,C.,Williamson,S.,Fountain,J.,Gossop,M.,
1999.Self-reportedoverdoseamonginjectingdrugusersinLondon,extentand
ThisresearchwasfundedbytheNationalHealthandMedical natureoftheproblem.Addiction94,471–478.
Quaglio,G.,Talamini,G.,Lechi,A.,Venturini,L.,Lugoboni,F.,GruppoIntersertDi
ResearchCouncil,andtheAustralianGovernmentDepartmentof
CollaborazioneScientifica,Mezzelani,P.,2001.Studyofheroin-relateddeaths
HealthandAgeing. innorth-easternItaly1985–98toestablishmaincausesofdeath.Addiction96,
127–1137.
Quan,V.,Vongchak,T.,Jittiwutikan,J.,Kawichai,S.,Srirak,N.,Wiboonnatakul,K.,
References Razak,M.K.,Suriyanon,V.,Celentano,D.D.,2007.Predictorsofmortalityamong
injecting and non-injecting HIV-negative drug users in northern Thailand.
Andrews, G., Hall, W., Teesson, M., Henderson, S., 1999. The Mental Health of Addiction102,441–446.
Australians:NationalSurveyofMentalHealthandWellbeing.Commonwealth Robins,L.N.,Helzer,J.E.,Croughan,J.,Ratcliff,K.S.,1981.NationalInstituteofMental
DepartmentofHealthandAgedCare,Canberra. HealthDiagnosticInterviewSchedule.Itshistory,characteristics,andvalidity.
Antolini,G.,Pirani,M.,Morandi,G.,Sorio,C.,2006.Genderdifferenceandmortality Arch.Gen.Psychiatry38,381–389.
inacohortofheroinusersintheprovincesofModenaandFerrara,1975–1999. Ross,J.,Teesson,M.,Darke,S.,Lynskey,M.,Ali,R.,Ritter,A.,Cooke,R.,2006.Short-
Epidemiol.Prev.30,91–99. term outcomes for the treatment of heroin dependence, findings from the
AustralianBureauofStatistics,2008.DeathsinAustralia,2008.AustralianBureau AustralianTreatmentOutcomeStudy(ATOS).Addict.Disord.TheirTreat.5,
ofStatistics,Canberra. 133–144.
Azim,T.,Chowdhury,E.I.,Reza,M.,Faruque,M.O.,Ahmed,G.,Khan,R.,Rahman, Ross, J., Teesson, M., Darke, S., Lynskey, M., Ali, R., Ritter, A., Cooke, R., 2005.
M.,Pervez,M.M.,Jana,S.,Strathdee,S.A.,2008.Prevalenceofinfections,HIV The characteristics of heroin users entering treatment, findings from the
riskbehavioursandfactorsassociatedwithHIVinfectionamongmaleinjecting Australian Treatment Outcome Study (ATOS). Drug Alcohol Rev. 24, 411–
drugusersattendinganeedle/syringeexchangeprograminDhaka,Bangladesh. 418.
Subst.UseMisuse43,2124–2144. Sanchez-Carbonell, X., Seus, L., 2000. Ten-year survival analysis of a cohort
Bargagli,A.M.,Hickman,M.,Davoli,M.,Perucci,C.A.,Schifano,P.,Buster,M.,Brugal, of heroin addicts in Catalonia, the EMETYST project. Addiction 95, 941–
T.,Vicente,J.,fortheCosmoWorkingGroup,2006.Drug-relatedmortalityand 948.
itsimpactonadultmortalityineightEuropeancountries.Eur.J.PublicHealth Soyka,M.,Apelt,S.,Lieb,M.,Wittchen,H.,2006.One-yearmortalityratesofpatients
16,198–202. receivingmethadoneandbuprenorphinemaintenancetherapy,Anationally
Bartu,A.,Freeman,N.C.,Gawthorne,G.S.,Codde,J.P.,Holman,D.J.,2004.Mortalityin representative cohort study in 2694 patients. J. Clin. Psychopharmacol. 26,
acohortofopiateandamphetamineusersinPerth,Western,Australia.Addiction 657–660.
99,60–63. SPSSinc.,2009.PASWStatistics,18.0.SPSSinc.,Chicago.
Bauer,S.M.,Loiple,R.,Jagsch,R.,Gruber,D.,Risser,D.,Tahu,K.,Fischer,G.,2008. Stenbacka, M., Liefman, L., Romelsjo, A., 2010. Mortality and cause of death
Mortalityinopioid-maintainedpatientsafterreleasefromanaddictionclinic. among1705illicitdrugusers,a37yearfollow-up.DrugAlcoholRev.29,21–
Eur.Addict.Res.14,82–91. 27.
S.Darkeetal./DrugandAlcoholDependence115 (2011) 190–195 195
Stoove, M.A., Dietze, P.M., Jolley, D., 2009. Overdose deaths following Vlahov,D.,Wang,C.,Ompad,D.,Fuller,C.M.,Caceres,W.,Ouellet,L.,Kerndt,P.,Des
previous non-fatal heroin overdose, record linkage of ambulance Jarlais,D.C.,Garfein,R.S.,2008.Mortalityriskamongrecent-onsetinjectiondrug
attendance and death registry data. Drug Alcohol Rev. 28, 347– usersinfiveUScities.Subst.UseMisuse43,413–428.
352. Ware,J.E.,Kosinski,M.,Keller,S.D.,1996.A12-itemShort-FormHealthSurvey,con-
Tait,R.J.N.,Hanh,T.T.,Hulse,G.,2008.Mortalityinheroinusers3yearsafternal- structionofscales,andpreliminarytestsofreliabilityandvalidity.Med.Care
trexoneimplantormethadonemaintenancetreatment.J.Subst.AbuseTreat. 34,220–233.
35,116–124. WorldHealthOrganization,1993.CompositeInternationalDiagnosticInterview
Teesson,M.,Mills,K.L.,Ross,J.,Darke,S.,Williamson,A.,Havard,A.,2008.The (Version1.1).WorldHealthOrganization,Vienna.
impact of treatment on 3 year outcomes for heroin dependence, findings Zhang,L.,Ruan,Y.H.,Yang,Z.N.,Liu,S.Z.,Zhou,F.,He,X.Y.,Yin,L.,Qin,G.M.,Shao,
from the Australian Treatment Outcome Study (ATOS). Addiction 103, 80– Y.M.,2005.A1-yearprospectivecohortstudyonmortalityofinjectingdrug
88. users.Chin.J.Epidemiol.26,190–193.
